Aspire Ventures Launches $300 Million Fund With Health System For Tech Supporting Precision Medicine

Aspire Universal (Aspire) recently launched a $300 million fund—the Aspire Ventures Precision Medicine Fund (AVP)—for investment in technology to support precision medicine. Lancaster General Health is a general partner in the fund, which builds upon a pre-existing collaboration between Aspire and Lancaster General Health.

Specifically, the fund will invest in AI development companies, as well as support technology being developed by the Smart Health Innovation Lab, a collaborative effort formed in 2017 by Aspire, Lancaster General Health, and capital BlueCross. AVP selects eight start-ups per year for a 12-week intensive certification process, expediting insurance reimbursement . . .